Staff reductions at the Food and Drug Administration could impede biomedical innovation in the US.
President Trump has stressed the importance of reestablishing America’s economic and strategic autonomy. This includes steps like revamping pharmaceutical manufacturing and minimizing regulatory burdens. That said, not all reforms are equally beneficial. Recent changes at the Food and Drug Administration, while perhaps well-intentioned, might undermine the innovation and domestic capabilities the President aims to bolster. […]
A Harris administration would be detrimental to biomedical innovation
America leads the world in biomedical innovation, and a Kamala Harris Administration poses an existential threat to that discovery and innovation, costing lives and jobs. Innovation has long been driven by strong intellectual property protections, strong federal investments in medical research funding, and supportive tax and regulatory policies. Produce almost twice as much medicine This […]